Predictive Oncology (POAI) said Thursday that it has developed two 3D liver toxicity models exclusively for Labcorp (LH).
The models simulate human and rat liver environments and can be used to evaluate and predict drug clearance, drug transport, and liver toxicity related to drugs, as well as provide insights into how cancer treatments might work in patients, according to the company.
Tests showed that the models were functional for up to 14 days, the company said.
Shares of Predictive Oncology were up 1.7%, while Labcorp was down 0.1% in recent trading.
Price: 1.00, Change: +0.02, Percent Change: +1.73
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.